|Bid||14.31 x 800|
|Ask||14.32 x 800|
|Day's Range||13.96 - 14.40|
|52 Week Range||10.26 - 20.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intrexon Corporation ("Intrexon" ...
NEW YORK , Sept. 14, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation ("Intrexon" or the "Company") (NYSE: XON). Such investors ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intrexon Corporation (“Intrexon” or “the Company”) (NYSE: XON) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Intrexon filed a Form 8-K with the SEC on August 9, 2018, announcement that the Company would restate its unaudited interim consolidated financial statements for the quarter ended March 31, 2018.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Intrexon Corporation resulting from allegations that Intrexon may have issued materially misleading business information to the investing public.
NEW YORK, Sept. 13, 2018-- Levi & Korsinsky announces it has commenced an investigation of Intrexon Corporation concerning possible violations of federal securities laws.. On August 9, 2018, Intrexon filed ...
Germantown-based biotech Intrexon Corp. is leaving the New York Stock Exchange for the Nasdaq, it announced Wednesday. "Following a careful review, we have concluded that our shareholders will be served better by our listing on Nasdaq, with its superior technology, trading liquidity, visibility and opportunities for investor outreach," Randal Kirk, Intrexon chairman and CEO, said in a release. Intrexon (NYSE: XON) will retain its XON ticker when it begins trading on the Nasdaq on Sept. 25.
Ticker symbol to remain "XON" GERMANTOWN, Md. , Sept. 12, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality ...
YELLOW SPRINGS, Ohio, Sept. 10, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has recommended amendment of the Association of American Feed Control Officials (AAFCO) ingredient definition of dried black soldier fly larvae (BSFL) to include feeding to poultry. The approval of BSFL for use in poultry feed expands the potential for this ingredient as a more sustainable source of protein and enables a nutritious, natural feed ingredient for poultry diets.
In a release issued earlier today by Ziopharm Oncology, Inc. (ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued. Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 18. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.
Ziopharm Oncology, Inc. (ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 8. In addition to Aisling Capital, Dr. Braunstein has held leadership positions including serving as the Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...
The Company is not announcing final financial results for the quarter ended June 30, 2018 and is delaying the filing of its quarterly report on Form 10-Q. The delay in filing the second quarter report is related to the Company's application of certain aspects of ASC 606 in the Company's first quarter Form 10-Q. The Company will be filing an amended Form 10-Q for the first quarter of 2018. The Company expects to file the second quarter report and amended first quarter report within the next few days. Intrexon and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme thebaine synthase.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Intrexon Corporation (NYSE: XON ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. ...
Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company’s annual meeting of stockholders.
MAYNARD, Mass., Aug. 07, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...
GERMANTOWN, Md. , Aug. 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
GERMANTOWN, Md. , Aug. 2, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.